Company news

Healios KK news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Shipment and Revenue Recognition of Initial Order of Culture Supernatant Products to JENECELL

October 5, 2026

Notice Regarding Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL

September 30, 2026

FY2026 Q2 Financial Results (Material)

August 12, 2026

Healios Selected for the AMED “Project to Promote the Industrialization of Regenerative/Cell Medicine and Gene Therapy”

July 26, 2026

Notice Regarding the Filing of a Counterclaim in Response to a Lawsuit Filed Against Healios

June 9, 2026

Healios K.K. to Present at Jefferies Global Healthcare Conference

November 11, 2025

Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference

October 20, 2025

Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025

TREASURE study results to be presented at the 14th World Stroke Congress

August 10, 2022

Exercise of Exclusive Option for a License Agreement with STEMAXON for the Development of UDC-Derived Photoreceptor Cells

July 12, 2022

Healios eNK Cells: Regenerative Medicine Product Quality Consultation with the PMDA for Planned Clinical Trials

July 12, 2022

Business Briefing for Institutional Investors

April 5, 2022

Progress Update in Relation to Application for Approval for HLCM051 for ARDS

April 4, 2022

Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke

April 4, 2022

Joint Research with the Division of Regenerative Medicine, the Institute of Medical Science for Developing a Mass Production Method of UDC Liver Buds

April 1, 2022

License Agreement with CellFiber Co., Ltd.

March 24, 2022

Notice of the Partial Amendments to Articles of Incorporation

February 24, 2022

Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors

February 24, 2022

Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus

February 24, 2022

Announcement of Change in Management

January 31, 2022

’ Gene-Edited NK Cells：Joint Research with Hiroshima University for Hepatocellular Carcinoma

December 20, 2021

FY2021 Q3 Financial Results

November 12, 2021

Announcement of Determination of the Issue Price and Other Matters for the Issuance of New Shares through an International Offering

September 15, 2021

Announcement of Issuance of New Shares through an International Offering

September 15, 2021

Successful differentiation of Healios UDCs into pancreatic β-cells in our joint research with the National Center for Global Health and Medicine

September 2, 2021

Full Enrolment of TREASURE Study for Patients with Ischemic Stroke

August 10, 2021

Decks